HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

@article{Gilbert2005HIV1VA,
  title={HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.},
  author={Peter B. Gilbert and Marta L. Ackers and Phillip W Berman and Donald P. Francis and Vladimir M. Popovic and Dale J. Hu and William L. Heyward and Faruk Sinangil and Bryan E Shepherd and Marc Gurwith},
  journal={The Journal of infectious diseases},
  year={2005},
  volume={192 6},
  pages={974-83}
}
The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5403 initially HIV-negative volunteers who were monitored for 3 years. The 368 subjects who acquired HIV-1 infection were monitored for 2 years by use of the following postinfection end points: plasma HIV-1 RNA level (viral load), CD4… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Cox model inferences on relative risks linked in two stages [technical report

T Cai, PB Gilbert, SG. Self
2004
View 10 Excerpts
Highly Influenced

Placebo - controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection

JB Margolick, H Farzadegan, DR Hoover, AJ Saah
J Infect Dis • 2005

Similar Papers

Loading similar papers…